MBP has developed a peptide known as AOD9604 derived from human...

MBP has developed a peptide known as AOD9604 derived from human growth hormone. The peptide has been proven to reduce fat by an average of 2.8kg over a twelve week period, with no adverse side effects. This is the first drug to target directly on fat metabolism as the mechanism for reducing weight. The successful phase 2b trial data enables the company to market its compound and secure a partnership opportunity with a major pharmaceutical company. A deal with a big pharmaceutical could take up to 12 months to resolve. Short term speculative investors should take profits while longer term holders should hold.